Search for a trial

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients
with Relapsed, Progressive or Refractory B-Cell Lymphoma

This study has been transitioned to CTIS with ID 2023-504802-12-00 check the CTIS register for the current data. Dose Escalation Objectives:Primary:* Determine maximum tolerated dose (MTD) and RP2DSecondary:* Establish tolerability of epcoritamab*…